Akari Therapeutics, Plc (AKTX): Analyst Consensus Forecast
The market for advanced biologics to combat rare inflammatory pathologies is still emerging, while demand in specialized clinics remains stable. The Akari Therapeutics (AKTX) business relies on the therapy of orphan conditions, where 25.44 profitability is secured by government insurance for life-saving medicines. This price chart confirms growth potential driven by post-merger asset synergy and successes in the development of the nomacopan inhibitor.
Analytical breakdowns for Akari Therapeutics plc (AKTX)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- balance sheet equity data:
- business debt structure and liquidity details:
Aggregate Debt to Equity Akari Therapeutics|AKTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Akari Therapeutics, Plc|AKTX - Company Aggregate Debts|Debts to Book Capitalization Akari Therapeutics plc|AKTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Akari Therapeutics|Quick Liquidity Indicator akaritx.com
- earnings and market ratios statistics:
AKTX - Net Profit|Projected Future Earnings Akari Therapeutics|AKTX - Price to Earnings Ratio|Future Price to Earnings Multiple Akari Therapeutics PLC|AKTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Akari Therapeutics plc|AKTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Akari Therapeutics|AKTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months akaritx.com|AKTX - Net earnings per share growth this year|Earnings growth forecast for next year Akari Therapeutics
General company analysis:AKTX akaritx.com
The investor determines the margin of safety for Akari Therapeutics (AKTX) via the average target price 25.44, which reflects analysts' aggregate assessment of the asset's fundamental value. The efficiency of biomaterial thermologistics directly impacts trial success, triggering stepped revisions of the market's target price for the stock and determining whether this biotech company maintains a speculative or investment-grade status.
Competitors of Akari Therapeutics
Analyst Consensus Forecast argenx.com (ARGX)|Price Target Chart BioNTech BNTX|Analyst Consensus Forecast Abivax SA ABVX|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|IMVT (Immunovant, Inc.) - Consensus Target|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|Kyverna Therapeutics (KYTX) - Price Target Chart|tizianalifesciences.com (TLSA) - Analyst Consensus Forecast|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Ventyx Biosciences Inc.|Price Target Chart Theratechnologies Inc (THTX)|AVTX (Avalo Therapeutics Inc) - Fair Value Consensus|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|Analyst Median Target agenusbio.com (AGEN)|CLYM: Consensus Target|Fair Value Consensus ZURA (zurabio.com)|ATYR (aTyr) - Consensus Target|ADAG: Analyst Forecast Prices|IMA (ImageneBio) - Analyst Consensus Forecast|STTK: Fair Value Consensus|Analyst Consensus Forecast EQ|CNTB - Average Forecast Price|Price Target Chart Immunic IMUX|Fair Value Consensus ATRA|InflaRx GmbH - Analyst Consensus Forecast|XFOR - Analyst Consensus Forecast|adicetbio.com (ACET) - Price Target Chart|Forecast Levels Chart CELU (Celularity)|INMB (INmune Bio Corp) - Analyst Consensus Forecast|Average Forecast Price Barinthus Biotherapeutics Corp BRNS|Consensus Target KZR (Kezar Life Sciences)|Analyst Consensus Forecast sabbiotherapeutics.com (SABS)|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Forecast Prices QTTB (Q32 Bio Inc)|GeoVax Labs Inc - Analyst Consensus Forecast|Analyst Median Target Edesa Biotech Corp EDSA|IBIO: Analyst Consensus Forecast|Consensus Target Carisma Therapeutics Inc.|Price Target Chart XTL Biopharmaceuticals Ltd.|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Analyst Consensus Forecast aptevotherapeutics.com (APVO)|Price Target Chart AIM ImmunoTech AIM|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI: Consensus Target|XORTX Therapeutics Inc - Analyst Forecast Prices|HIND (ReShape Lifesciences) - Consensus Target|Broker Consensus Forecast REVB|Price Target Chart Indaptus Therapeutics|scinai.com - Forecast Levels Chart|Analyst Consensus Forecast CALI|AFMD (affimed.com) - Fair Value Consensus|Analyst Consensus Forecast ALLK (Allakos)|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|Fair Value Consensus ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price Target Chart|Consensus Target TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
